Fig. 2.

Outcomes from the subset of patients with confirmed IDH-mutant LGGs enrolled on a phase II clinical trial of TMZ monotherapy for high-risk LGG. (A) Overall survival and (B) progression-free survival are reported from the time of trial enrollment. Time from trial enrollment to histologic confirmation of high-grade transformation is shown for (C) the subset of confirmed IDH-mutant gliomas and (D) stratified by initial tumor volume on T2-weighted imaging. Abbreviations: IDH, isocitrate dehydrogenase; LGG, low-grade glioma; TMZ, temozolomide.